BSQ’s Abecma CAR-T Multiple Myeloma Therapy Cuts Progression or Death in Half

Bristol Myers Squibb has released positive new data from its KarMMa-3 trial for Abecma, its CAR-T therapy for multiple myeloma. The results show that patients taking Abecma instead of the current standard of care have 51% reduced risk of death or disease progression. Data also indicates that patients in the Abecma group had a median time without disease progression of 13.3 months.

According to Angus Liu, “The trial marks “a major milestone” as the first randomized study for a CAR-T therapy in multiple myeloma, and the investigators who saw the results were “ecstatic,” Nick Leschly, CEO of BMS’ partner 2seventy bio, said in an interview with Fierce Pharma ahead of the data release.”

To read more, click here.

(Source: Fierce Pharma, February 10th, 2023)